Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 15/20 | 0.80 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.66 |
| ▸ | MAPT | P10636 | 4/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.66 |
| ▸ | ESRRG | P62508 | 3/20 | 0.66 |
| ▸ | MEN1 | O00255 | 3/20 | 0.66 |
| ▸ | PGR | P06401 | 3/20 | 0.66 |
| ▸ | TP53 | P04637 | 2/20 | 0.66 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.66 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.66 |
| ▸ | LMNA | P02545 | 1/20 | 0.66 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.66 |
| ▸ | PLD2 | O14939 | 1/20 | 0.66 |
| ▸ | ESRRB | O95718 | 1/20 | 0.66 |
| ▸ | PLD1 | Q13393 | 1/20 | 0.66 |
| ▸ | EBP | Q15125 | 4/20 | 0.65 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.65 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5079405 | 1.00 | ESR1 (0.80) | ESR1ESR2MAPTKMT2AESRRG | |
| SCHEMBL1152821 | 1.00 | ESR1 (0.80) | ESR1ESR2MAPTKMT2AESRRG | |
| SCHEMBL10878031 | 0.93 | ESR1 (0.70) | ESR1ESR2MAPTKMT2AESRRG | |
| SCHEMBL10878039 | 0.93 | ESR1 (0.70) | ESR1ESR2MAPTKMT2AESRRG | |
| SCHEMBL17164682 | 0.91 | ESR1 (0.79) | ESR1ESR2MAPTKMT2AESRRG | |
| SCHEMBL17164687 | 0.91 | ESR1 (0.79) | ESR1ESR2MAPTKMT2AESRRG | |
| Droloxifene SCHEMBL4843 | 0.90 | ESR1 (0.82) | ESR1ESR2MAPTKMT2AESRRG | |
| Droloxifene SCHEMBL30728607 | 0.90 | ESR1 (0.82) | ESR1ESR2MAPTKMT2AESRRG | |
| Droloxifene SCHEMBL1151787 | 0.90 | ESR1 (0.82) | ESR1ESR2MAPTKMT2AESRRG | |
| Droloxifene SCHEMBL5030004 | 0.90 | ESR1 (0.82) | ESR1ESR2MAPTKMT2AESRRG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5047431-A | TREATMENT OF HORMONE-DEPENDENT MAMMARY TUMORS; ANTIESTROGENS | KLINGE PHARMA GMBH & CO. (DE) | 1991-09-10 | — | — | US | claimed |
| US-20130289024-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES | U.S. ARMY MEDICAL RESEARCH AND MATERIEL COMMAND | 2013-10-31 | — | — | US | disclosed |
| US-8475804-B2 | Compositions and methods for treatment of filovirus-mediated diseases | U.S. ARMY MEDICAL RESEARCH AND MATERIAL COMMAND (US) | 2013-07-02 | — | — | US | disclosed |
| US-20110028564-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES | ZALICUS INC. | 2011-02-03 | — | — | US | disclosed |
| US-5047431-A | TREATMENT OF HORMONE-DEPENDENT MAMMARY TUMORS; ANTIESTROGENS | KLINGE PHARMA GMBH & CO. (DE) | 1991-09-10 | — | — | US | disclosed |
| EP-0054168-B1 | 1,1,2-TRIPHENYL-BUT-1-ENE DERIVATIVES, PROCESS FOR THEIR MANUFACTURE AND THEIR USE AS PHARMACEUTICAL AGENTS | Klinge Pharma GmbH (DE) | 1984-07-11 | — | — | EP | disclosed |
| EP-0054168-A1 | 1,1,2-Triphenyl-but-1-ene derivatives, process for their manufacture and their use as pharmaceutical agents | Klinge Pharma GmbH (DE) | 1982-06-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028564-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES | FLNA, FLNB, PIGS | ESR1 4577/4885ESR2 4164/4885MAPT 1583/4885 |
| US-20130289024-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES | FLNA, FLNB, PIGS | ESR1 4577/4885ESR2 4164/4885MAPT 1583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.